Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain

N Jantaratnotai1, C Schwab, J K Ryu

  • 1Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.

Insights

Alzheimer

Area of Science:

  • Neuroscience
  • Pathology
  • Immunology

Background:

  • Alzheimer's disease (AD) is characterized by neuroinflammation and vascular changes.
  • Microglial activation and altered cerebral microvasculature are observed in AD brains.

Purpose of the Study:

  • To investigate microvascular properties and their association with microglial clusters in Alzheimer's disease cortical tissue.
  • To explore the role of microglial-vascular interactions in AD pathogenesis.

Main Methods:

  • Immunostaining for laminin and von Willebrand factor to assess microvasculature.
  • Quantification of microvessel density and microglial clusters.
  • Analysis of extravascular proteins (laminin, fibrinogen) and inflammatory factors (TNF-α, VEGF).

Main Results:

  • Increased microvessel density and proangiogenic activity in severe AD (ADsev) brains.
  • Evidence of vascular remodeling and extravascular laminin in ADsev.
  • Progressive microgliosis from non-demented (ND) to mild AD (ADmild) to ADsev, with clustered microglia in ADsev.
  • Proximity of microglial clusters to extravascular laminin and fibrinogen in ADsev.
  • Elevated TNF-α and VEGF associated with microglial clusters in ADsev.

Conclusions:

  • Microglial clusters are associated with vascular abnormalities and inflammatory factors in severe AD.
  • Microglial-induced vascular remodeling and reciprocal interactions may drive AD inflammation.
  • These findings suggest a critical role for microglial-vascular crosstalk in AD progression.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...